Histopathological Features of L-Asparaginase-Induced Liver Disease

ABSTRACT

We studied the histopathological changes of liver in four patients who developed hepatomegaly and abnormal liver chemistry tests 2 to 20 days following administration of L-asparaginase as a part of a combination chemotherapy regimen for treatment of acute lymphoblastic leukemia. The severity of the liver disease due to L-asparaginase was unpredictable. One patient developed acute fulminant hepatic failure and required liver transplantation. The most consistent pathological change, observed in all four cases, was diffuse steatosis. Other changes included patchy hepatocyte necrosis, mixed inflammatory cell infiltrates in the portal tracts, and variable degrees of hepatocellular, or canalicular cholestasis, or a combination of these.

KEYWORDS

Drug-induced liver disease - L-asparaginase toxicity - steatosis

REFERENCES

• 1 Asparaginase Lexi Comp Inc, 1978-2001; 1-6 Available at: uchtrans01/crl/chapter/mono/hf008900.htm . 
• 2 Cairo M S. Adverse reactions of L-asparaginase.  Am J Pediatr Hematol Oncol . 1982;  4 335-339
• 3 Cetin M, Yetgin S, Kara A. et al . Hyperglycemia, ketoacidosis and other complications of L-asparaginase in children with acute lymphoblastic leukemia.  J Med . 1994;  25 219-229
• 4 Schein P S, Rakieten N, Gordon B M, Davis R D, Rall D P. The toxicity of Escherichia coli L-asparaginase.  Cancer Res . 1969;  29 426-434
• 5 Biggs J C, Chesterman C N, Holliday J. L-asparaginase-clinical experience in leukemia, lymphoma and carcinoma.  Aust N Z J Med . 1971;  1 1-7
• 6 Woods J S, Handschumacher R E. Hepatic hemostasis of plasma L-asparagine.  Am J Physiol . 1971;  221 1785-1790
• 7 Durden D L, Salazar A M, Distasio J A. Kinetic analysis of hepatotoxicity associated with anti-neoplastic asparaginases.  Cancer Res . 1983;  43 1602-1605
• 8 Park Y K, Abuchowski A, Davis S, Davis F. Pharmacology of Escherichia coli-A-ase polyethylene glycol adduct.  Anticancer Res . 1981;  1 373-376
• 9 Muller H J, Loning L, Horn A. et al . Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols.  Br J Haematol . 2000;  110 379-384
• 10 Snyder L S, Heigh R I, Anderson M I. Cyclophosphamide-induced hepatotoxicity in a patient with Wegener's granulomatosis.  Mayo Clin Proc . 1993;  68 1203-1204
• 11 Mok C C, Wong W M, Shek T W. et al . Cumulative hepatotoxicity induced by continuous low-dose cyclophosphamide therapy.  Am J Gastroenterol . 2000;  95 845-846
• 12 Goldberg J W, Lidsky M D. Cyclophosphamide-associated hepatotoxicity.  South Med J . 1985;  78 222-223
• 13 Locasciulli A, Mura R, Fraschini D. et al . High-dose methotrexate administration and acute liver damage in children treated for acute lymphoblastic leukemia. A prospective study.  Haematologica . 1992;  77 49-53
• 14 El Saghir S N, Hawkins K A. Hepatotoxicity following vincristine therapy.  Cancer . 1984;  54 2006-2008
• 15 Ortega J A, Donaldson S S, Ivy S P, Pappo A, Maurer H M. Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Children Cancer Group, the Pediatric Oncology Group, and the Pediatric Intergroup Statistical Center.  Cancer . 1997;  79 2435-2439
• 16 Ayash L J, Hunt M, Antman K. et al . Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas.  J Clin Oncol . 1990;  8 1699-1706
• 17 Koren G, Beatty K, Seto A, Einarson T R, Lishner M. The effects of impaired liver function on the elimination of antineoplastic agents.  Ann Pharmacother . 1992;  26 363-371